ERG and prostate neoplasm: The Toronto cohort, a subset of that previously characterised for clinical markers (Nam et al, 2007), includes 69 patients with TMPRSS2–ERG T1/E4 fusion-positive tumours and 70 prostate tumours that were TMPRSS2–ERG fusion negative.